🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

!!!NEWSFLASH!!! Long-term outcomes of the TAVI low risk trials. #PCRLV 🎯 The SAPIEN 3 and EVOLUT Low Risk trials offer an optimal platform for assessing the long-term durability of TAVI versus surgery. 🎯 Use of the surgical arm of these trials as a reference to compare the

SAVE THE DATE - SWISS CTO&CHIP

Shortening in-hospital stay after transcatheter aortic valve implantation: a déjà vu in percutaneous interventions. Read the latest Editorial in EHJ: academic.oup.com/eurheartj/adva… #TAVI #cardiotwitter European Society of Cardiology Journals European Society of Cardiology

Presented today at #ACC24: In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: nej.md/3xyXU3t

Presented at #ACC24: Hospitalized patients with acute myocardial infarction & preserved EF were assigned to receive open-label long-term beta-blocker therapy or not. Beta-blockers did not lead to a lower risk of death or MI. Full REDUCE-AMI trial results: nej.md/4akVhRx

In the SMART trial of TAVR in patients with a small aortic annulus, a self-expanding valve was noninferior to a balloon-expandable valve for clinical outcomes and was superior for bioprosthetic-valve dysfunction through 12 months. Full results: nej.md/49p7VO7 #ACC24

Congratulations to this amazing work. Real world data showing great outcomes for TAVI patients in comparison with SAVR!!

A randomized trial that enrolled pts with severe aortic stenosis at low or intermediate surgical risk showed that transcatheter aortic-valve implantation was noninferior to surgical aortic-valve replacement at 1 year. Full DEDICATE-DZHK6 trial results: nej.md/3TLx8MT

First #TAVI Sapien S3 Ultra Resilia UniSpitalBaselCH Switzerland in a challenging tortouos and horzontal aorta with a great result and a great team. Felix Mahfoud Gregor Leibundgut @J_Boeddinghaus Christoph Kaiser, Yves Bayard, Mohamed Bayoumi

Are you looking for a fellowship in clinical research and structural cardiology? Apply now and join our team! Felix Mahfoud Gregor Leibundgut @J_Boeddinghaus linkedin.com/jobs/view/4000…

🚨 RESHAPE-HF2 trial: TEER is better than medical therapy alone in patients with heart failure and MR 😷 505 patients with HF with LVEF 20%-50% and severe MR, not eligible for surgery, randomised to M-TEER + OMT or OMT alone 📲 nejm.org/doi/full/10.10… #ESCCongres2024

In MATTERHORN, among patients with heart failure and secondary mitral regurgitation, transcatheter edge-to-edge repair was noninferior to mitral-valve surgery with respect to a composite of death, rehospitalization for heart failure, stroke, reintervention, or implantation of an

#ESC24 #ACS2_ Clinical case session. "Contenido dirigido a profesionales sanitarios” It has been a pleasure to co-moderate this session with Dr.Thomas Nestelberguer Thomas Nestelberger 1⃣SCAD: Predomina en mujeres; su mecanismo no se comprende totalmente. Se recomienda manejo

🚨 POPular PAUSE trial: how to manage anticoagulation during TAVI? 😷 869 patients with severe AS with long term OAC randomized to a continued or interrupted OAC strategy 📈 Continuation was not noninferior to interruption for the primary composite endpoint #ESCCongress2024

EARLY TAVR published. Among patients with asymptomatic severe aortic stenosis, a strategy of early TAVR was superior to clinical surveillance in reducing the incidence of death, stroke, or unplanned hospitalization for cardiovascular causes, driven by the latter. The study's

Gamechanger!!!

The inflammatory pathway offers a potential therapeutic target in patients undergoing TAVR: in the Co-STAR trial treatment with colchicine was associated with a lower risk of cardiac arrhythmias and subclinical leaflet thrombosis at 30 days. #TCT2024

2025 US guidelines for the management of ACS (STEMI and NSTE-ACS) just released. Insertion of a microaxial flow pump (Impella) to prevent death in in cardiogenic shock has received a class IIa LOE B-R recommendation. IABP and VA-ECMO are class III for rourine use.

Prognostic impact of atrial fibrillation in patients undergoing transcatheter aortic valve implantation, by Thomas Nestelberger and colleagues UniSpitalBaselCH #EPeeps heartrhythmopen.com/article/S2666-…

Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation: NEJM 🥸 Trials at #ACC25 - Dapagliglozin in pts with TAVR! 😱 Summary 👇👇👇👇